{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T06:25:51Z","timestamp":1766557551135,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"United States Department of Agriculture\/National Institute of Food and Agriculture","award":["2020-67016-31543"],"award-info":[{"award-number":["2020-67016-31543"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Rift Valley fever virus (RVFV) is considered to be a high biodefense priority based on its threat to livestock and its ability to cause human hemorrhagic fever. RVFV-infected livestock are also a significant risk factor for human infection by direct contact with contaminated blood, tissues, and aborted fetal materials. Therefore, livestock vaccination in the affected regions has the direct dual benefit and one-health approach of protecting the lives of millions of animals and eliminating the risk of severe and sometimes lethal human Rift Valley fever (RVF) disease. Recently, we have developed a bovine herpesvirus type 1 (BoHV-1) quadruple gene mutant virus (BoHV-1qmv) vector that lacks virulence and immunosuppressive properties due to the deletion of envelope proteins UL49.5, glycoprotein G (gG), gE cytoplasmic tail, and US9 coding sequences. In the current study, we engineered the BoHV-1qmv further by incorporating a chimeric gene sequence to express a proteolytically cleavable polyprotein: RVFV envelope proteins Gn ectodomain sequence fused with bovine granulocyte-macrophage colony-stimulating factor (GMCSF) and Gc, resulting in a live BoHV-1qmv-vectored subunit vaccine against RVFV for livestock. In vitro, the resulting recombinant virus, BoHV-1qmv Sub-RVFV, was replicated in cell culture with high titers. The chimeric Gn-GMCSF and Gc proteins expressed by the vaccine virus formed the Gn\u2013Gc complex. In calves, the BoHV-1qmv Sub-RVFV vaccination was safe and induced moderate levels of the RVFV vaccine strain, MP12-specific neutralizing antibody titers. Additionally, the peripheral blood mononuclear cells from the vaccinated calves had six-fold increased levels of interferon-gamma transcription compared with that of the BoHV-1qmv (vector)-vaccinated calves when stimulated with heat-inactivated MP12 antigen in vitro. Based on these findings, we believe that a single dose of BoHV-1qmv Sub-RVFV vaccine generated a protective RVFV-MP12-specific humoral and cellular immune response. Therefore, the BoHV-1qmv sub-RVFV can potentially be a protective subunit vaccine for cattle against RVFV.<\/jats:p>","DOI":"10.3390\/v15112183","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T12:50:42Z","timestamp":1698670242000},"page":"2183","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Novel Quadruple Gene-Deleted BoHV-1-Vectored RVFV Subunit Vaccine Induces Humoral and Cell-Mediated Immune Response against Rift Valley Fever in Calves"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-0808","authenticated-orcid":false,"given":"Selvaraj","family":"Pavulraj","sequence":"first","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-5175","authenticated-orcid":false,"given":"Rhett W.","family":"Stout","sequence":"additional","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise D.","family":"Barras","sequence":"additional","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel B.","family":"Paulsen","sequence":"additional","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-5512","authenticated-orcid":false,"given":"Shafiqul I.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4049\/jimmunol.62.2.213","article-title":"Rift Valley fever: Accidental infections among laboratory workers","volume":"62","author":"Smithburn","year":"1949","journal-title":"J. Immunol."},{"key":"ref_2","first-page":"867","article-title":"Rift Valley fever affecting humans in South Africa: A clinicopathological study","volume":"51","author":"Meyer","year":"1977","journal-title":"S. Afr. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1128\/JVI.02341-13","article-title":"Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets","volume":"88","author":"Hartman","year":"2014","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","article-title":"Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins","volume":"357","author":"Gerrard","year":"2007","journal-title":"Virology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Faburay, B., LaBeaud, A.D., McVey, D.S., Wilson, W.C., and Richt, J.A. (2017). Current Status of Rift Valley Fever Vaccine Development. Vaccines, 5.","DOI":"10.3390\/vaccines5030029"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41541-020-0166-9","article-title":"Rift Valley fever virus vaccination induces long-lived, antigen-specific human T cell responses","volume":"5","author":"Harmon","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tran, A., Trevennec, C., Lutwama, J., Sserugga, J., Gely, M., Pittiglio, C., Pinto, J., and Chevalier, V. (2016). Development and Assessment of a Geographic Knowledge-Based Model for Mapping Suitable Areas for Rift Valley Fever Transmission in Eastern Africa. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004999"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3201\/eid1203.050973","article-title":"Rift Valley Fever potential, Arabian Peninsula","volume":"12","author":"Anyamba","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J. Gen. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0264-410X(90)90096-5","article-title":"Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine","volume":"8","author":"Saluzzo","year":"1990","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-1702(97)00097-X","article-title":"Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation","volume":"52","author":"Vialat","year":"1997","journal-title":"Virus Res."},{"key":"ref_12","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J. Vet. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley fever vaccines: An overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"Ikegami","year":"2017","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ly, H.J., Lokugamage, N., Nishiyama, S., and Ikegami, T. (2017). Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185194"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3201\/eid1712.111035","article-title":"Molecular epidemiology of Rift Valley fever virus","volume":"17","author":"Grobbelaar","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.vaccine.2010.01.001","article-title":"Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vetimm.2018.01.001","article-title":"Expression of cytokines following vaccination of goats with a recombinant capripoxvirus vaccine expressing Rift Valley fever virus proteins","volume":"197","author":"Ghram","year":"2018","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol. J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hao, M., Bian, T., Fu, G., Chen, Y., Fang, T., Zhao, C., Liu, S., Yu, C., Li, J., and Chen, W. (2023). An adenovirus-vectored RVF vaccine confers complete protection against lethal RVFV challenge in A129 mice. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1114226"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lopez-Gil, E., Moreno, S., Ortego, J., Borrego, B., Lorenzo, G., and Brun, A. (2020). MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses. Vaccines, 8.","DOI":"10.3390\/vaccines8010082"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1089\/vbz.2014.1650","article-title":"A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep","volume":"14","author":"Faburay","year":"2014","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fvets.2020.00062","article-title":"Immunogenicity Assessment of Rift Valley Fever Virus Virus-Like Particles in BALB\/c Mice","volume":"7","author":"Li","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chowdhury, S.I., Pannhorst, K., Sangewar, N., Pavulraj, S., Wen, X., Stout, R.W., Mwangi, W., and Paulsen, D.B. (2021). BoHV-1-Vectored BVDV-2 Subunit Vaccine Induces BVDV Cross-Reactive Cellular Immune Responses and Protects against BVDV-2 Challenge. Vaccines, 9.","DOI":"10.3390\/vaccines9010046"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1016\/j.vaccine.2014.07.004","article-title":"A triple gene mutant of BoHV-1 administered intranasally is significantly more efficacious than a BoHV-1 glycoprotein E-deleted virus against a virulent BoHV-1 challenge","volume":"32","author":"Chowdhury","year":"2014","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1128\/JVI.00379-08","article-title":"A bovine herpesvirus type 1 mutant virus specifying a carboxyl-terminal truncation of glycoprotein E is defective in anterograde neuronal transport in rabbits and calves","volume":"82","author":"Liu","year":"2008","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Daniels, R.W., Rossano, A.J., Macleod, G.T., and Ganetzky, B. (2014). Expression of multiple transgenes from a single construct using viral 2A peptides in Drosophila. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100637"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/JVI.78.9.4806-4816.2004","article-title":"A glycine-rich bovine herpesvirus 5 (BHV-5) gE-specific epitope within the ectodomain is important for BHV-5 neurovirulence","volume":"78","author":"Zhou","year":"2004","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pavulraj, S., Pannhorst, K., Stout, R.W., Paulsen, D.B., Carossino, M., Meyer, D., Becher, P., and Chowdhury, S.I. (2022). A Triple Gene-Deleted Pseudorabies Virus-Vectored Subunit PCV2b and CSFV Vaccine Protects Pigs against PCV2b Challenge and Induces Serum Neutralizing Antibody Response against CSFV. Vaccines, 10.","DOI":"10.3390\/vaccines10020305"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Phoenix, I., Nishiyama, S., Lokugamage, N., Hill, T.E., Huante, M.B., Slack, O.A., Carpio, V.H., Freiberg, A.N., and Ikegami, T. (2016). N-Glycans on the Rift Valley Fever Virus Envelope Glycoproteins Gn and Gc Redundantly Support Viral Infection via DC-SIGN. Viruses, 8.","DOI":"10.3390\/v8050149"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.coviro.2012.02.017","article-title":"Breaking the chain: Rift Valley fever virus control via livestock vaccination","volume":"2","author":"Bird","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4269\/ajtmh.2010.09-0293","article-title":"Risk factors for severe Rift Valley fever infection in Kenya, 2007","volume":"83","author":"Anyangu","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1128\/JVI.76.23.12200-12210.2002","article-title":"Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein","volume":"76","author":"Gerrard","year":"2002","journal-title":"J. Virol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/11\/2183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:14:19Z","timestamp":1760130859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/11\/2183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["v15112183"],"URL":"https:\/\/doi.org\/10.3390\/v15112183","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}